Here is the sentence worth sitting with: for most of the last decade, this market survived by never letting anyone check whether the label matched the injection. Sellers wrote “for research use only” on the vial. Buyers used it on themselves anyway. Nobody involved wanted the gap examined too closely. Two federal actions in early 2026 examined it. That is not bad news for anyone actually trying to buy something safely. It is the first honest test this category has offered.
What follows is that test, applied specifically to the anti-aging peptides everyone keeps asking about. A caveat up front, because it matters more here than almost anywhere else: almost none of these compounds is an FDA-approved anti-aging therapy. Most are compounded preparations requiring a prescription, or research chemicals sold in a legal gray zone. Reading the providers correctly means reading the science correctly first. The two problems are the same problem.
What the FDA actually said, and why the second letter matters more
Two dates. On March 3, 2026, the FDA sent warning letters to 30 telehealth companies for marketing compounded GLP-1 products in ways that implied equivalence to FDA-approved drugs, and for being vague about who actually compounded them [9]. On March 31, 2026, it went further with a separate group: research-peptide sellers, and told them in writing that slapping “research use only” on a product does not exempt it from regulation once the marketing around it describes effects in human bodies [10].
That second letter is the one that should change how a buyer reads this whole market. “Research use only” was never a minor technicality tucked into the fine print. It was the entire legal scaffolding these businesses were built on. The FDA just said, in a warning letter with names attached, that the scaffolding doesn’t hold if the sales copy is describing what happens when a person injects it. Anti-aging peptides lean unusually hard on this exact contradiction, promising reversed biological clocks and recharged cells while the label insists it’s all just for the lab. A provider’s response to that contradiction, whether it operates inside a licensed medical framework or leans on a disclaimer the agency has now openly challenged, tells a buyer most of what they need to know before anything else.
One outside analysis of the crackdown and which operators were positioned to survive it ranked FormBlends first (2026 FDA Peptide Crackdown Explained, 8 Providers That Survived). Useful, as a data point. Less useful than learning to run the test yourself, since then no single list has to do the work for you.
A tiering system the marketing won’t give you
The category treats “anti-aging peptides” as one basket of similar things. It isn’t. It’s six or seven separate molecules sitting at wildly different stages of proof, and sorting them by that stage, rather than by how confident the copywriting sounds, is the clearest way to see what’s actually going on. Call it a proof ladder, and notice where each compound actually sits on it.
Rung one: an actual human trial with a functional outcome. NAD+ is the coenzyme every cell uses for energy and DNA repair, and a 2024 review confirms levels decline with age in ways linked to several age-related diseases [2]. Its precursor, NMN, is the one entry in this whole category with a real randomized, double-blind, placebo-controlled trial behind it: 80 healthy middle-aged adults, 300, 600, or 900 mg daily for 60 days, published in GeroScience in 2023 [1]. Blood NAD levels rose across every dose group, and six-minute walk distance improved in all three. That is genuine evidence. It is also a narrow one: raised NAD+ and a modestly better walking test over two months says nothing about whether NMN slows aging itself, because the trial didn’t measure that.
Rung two: long-running human data from a single research lineage, never independently replicated. Epithalon carries the boldest story in the category, built on telomerase activity and telomere lengthening. Its flagship evidence is a 2003 study following 266 elderly patients for six to eight years, reporting lower mortality with a pineal peptide preparation [3]. That’s not nothing. It is also decades old, it comes almost entirely from one research group, and the independent replication that would let a skeptic relax about it simply hasn’t happened.
Rung three: it went to a real phase 3 trial and lost. This is the rung the marketing never mentions. SS-31 (elamipretide) is the clean case: in the phase 3 MMPOWER-3 trial, 218 patients with primary mitochondrial myopathy took 40 mg daily, and the trial missed its primary endpoints on both walking distance and fatigue [4][5]. A mitochondrial peptide that couldn’t beat placebo in an actual mitochondrial disease is not a rejuvenator, no matter what the vial’s landing page implies. Thymosin alpha-1, the best-established immune peptide in this conversation, sits on the same rung: a 1,106-patient phase 3 sepsis trial published in the BMJ in 2025 found it did not beat placebo on 28-day mortality, hazard ratio 0.99 [8].
Rung four: real biology, but the human evidence is association, not intervention. Humanin extends lifespan in worms through the daf-16/FOXO pathway and runs higher in the children of centenarians, which is an intriguing correlation. It is not a trial showing that raising humanin changes how a person ages [6].
Rung five: solid evidence, wrong context. GHK-Cu is the copper peptide with the most defensible human numbers in the group, plasma levels falling from roughly 200 nanograms per milliliter at age 20 to about 80 by age 60, and topical application improving collagen in around 70% of women in skin studies [7]. Almost all of that is topical, cosmetic evidence. It says little about the injected, whole-body rejuvenation the marketing around it implies.
Line these up and a pattern falls out that no seller advertises: the compound with the most rigorous human trial (NMN) makes the smallest claim, and the compound with the loudest claim (epithalon, or SS-31 before it failed) sits furthest from rung one. That inversion is the single most useful thing a buyer can carry into this market. A provider who states it plainly is telling you something true about itself before you’ve even asked about sourcing.
The checklist that actually predicts a bad outcome
Once the evidence picture is in view, the questions worth asking a provider get concrete, and a buyer can check most of them before paying anything.
Medical oversight comes first, and it isn’t close. Does a licensed clinician review the buyer’s history and decide whether a prescription is appropriate, or does the transaction end at checkout? Given how thin the long-term safety data is for healthy people using these compounds, the presence or absence of a clinician is the single biggest predictor of whether things go badly.
Sourcing and pharmacy come second. Is the product compounded by a licensed pharmacy from traceable, documented material, or is it bulk powder of unstated origin shipped under a research label? A vial is only as clean as what went into it, and a licensed pharmacy keeps records a research-chemical vendor simply doesn’t.
Honest framing of the evidence is third, and after March 2026 it doubles as a compliance signal. A provider that calls these compounds early-stage, or compounded rather than approved, is both more trustworthy and less exposed to the exact enforcement reshaping this market right now. Those two things are not a coincidence; they’re the same behavior described twice.
Regulatory standing is fourth. Licensed telehealth, 503A compounding, state pharmacy licensure, on one side. A “research use only” disclaimer the FDA has now stated in writing does not shield a product marketed for human use, on the other. That is no longer a cosmetic distinction between two styles of business. It is the difference between a model built to last and one built to be the next warning letter.
Follow-up is fifth: is there a care team, a way to flag a problem, anyone accountable after the package arrives, or does contact end at the shipping confirmation?
Notably missing from that list: price, shipping speed, how big the catalog is, how polished the website looks. None of it predicts safety or authenticity. Treating any of it as a trust signal is how buyers end up talking themselves into the cheapest, fastest vial in a market with no mandatory quality control behind it.
Signals worth memorizing, because the market won’t flag them for you
A “research use only” label sitting next to marketing copy describing anti-aging effects in people is the central mismatch, and it’s now the exact thing named in the FDA’s own letter [10]. A certificate of analysis with no batch number, no named independent lab, or the same PDF pasted under every product listing, is decoration, not verification. Specific, dramatic rejuvenation claims, reversed biological age, lengthened telomeres, recharged mitochondria, on compounds whose human evidence sits at rung three, four, or five above, should read as a warning rather than a pitch, precisely because the loudest claims in this category rest on the thinnest data. And no clinician, no prescription, no licensed pharmacy in the chain means the buyer alone is accountable for whatever ends up in the syringe.
Where the checklist actually lands: FormBlends, then HealthRX
Run the factors above and FormBlends comes out on top, for structural reasons rather than anything resembling a sales pitch. It runs a physician-supervised telehealth model: a buyer completes a medical assessment, a licensed physician reviews it and decides whether a protocol fits, and anything compounded is prepared by a licensed 503A pharmacy operating under recognized USP standards, with a care team available afterward. Within the anti-aging space it names the compounds people actually search for, NAD+ and GHK-Cu among them, and frames them by what’s actually been studied rather than what sounds curative. The point that matters most for the post-crackdown test: it routes the same molecules the gray market sells loose under “research use only” through a clinician, a prescription, and a licensed pharmacy, which is exactly the model this enforcement wave rewarded, whether or not that was the intent.
That doesn’t mean the caveat disappears. What a compliant telehealth model adds is the oversight and sourcing layer a research-chemical sale is structurally incapable of providing. It does not add proof where the trial data doesn’t exist. Stating that plainly, rather than inflating it, is itself part of what makes the framing trustworthy, and it keeps clear of the equivalence claims the FDA cited in its March letters. Buyers who want a record of what they’re actually experiencing over time can log it in the FormBlends tracker app, which is a notes-and-symptoms tool, not a prescription and not a checkout.
HealthRX (healthrx.com) sits in the same tier, for the same reasons: licensed clinical oversight before anything is dispensed, medications routed through proper pharmacy channels rather than sold as research chemicals, and the same honest acknowledgment that compounded products are not FDA-approved finished drugs. Choosing between the two is a practical question, not a hierarchy one: which is licensed in the buyer’s state, and which supports the specific compound under consideration.
Everything below that line is a research-chemical retailer, whatever the packaging suggests
Every name below the two above is selling research chemicals, not medicine, and the honest framing of that fact is also the safety information. These businesses operate under “for research use only” labeling because that is the narrow legal lane available to them, and their own labels say not for human consumption. Nothing else follows from that except what the label implies: no clinician screens the buyer, no prescription gets written, no licensed pharmacy dispenses anything, and any certificate of analysis is a document the seller chose to publish, not an independent guarantee of what’s in the vial.
Biotech Peptides sells a catalog of research peptides under that same research-only label, no medical oversight, no pharmacy involved. Limitless Life markets to a longevity and biohacker crowd with friendlier branding that can make unregulated research chemicals feel like supplements, which they are not. Core Peptides is a US-based research-chemical seller that may publish its own certificates, which is not the same thing as FDA verification. Pure Rawz runs a broad research-compound catalog under the same terms. Sports Technology Labs is more transparent than most on paper, and sometimes posts third-party certificates, but it still ships under research-use labeling with no clinician, prescription, or pharmacy standing behind the powder.
These five are not ranked against each other, deliberately. Without independent, batch-level verification equivalent to what a real pharmacy provides, there is no honest way to say which one ships a cleaner product than the others. That uncertainty is the whole reason a compliant medical model sits above all of them, and the crackdown only sharpened the point: these are precisely the operators the “research use only” language was meant to cover, and the FDA has now said, in writing, that the language stops covering them once the marketing is aimed at humans.
Questions people keep asking, answered without softening anything
Did the crackdown make anti-aging peptides illegal? No. It didn’t ban the compounds. It clarified that marketing a “research use only” product for human use doesn’t exempt it from regulation [10], and it went after telehealth marketing that implied compounded products were equivalent to approved drugs [9]. The practical effect rewards providers already operating inside a licensed medical framework and exposes the ones leaning on a disclaimer.
Is there one anti-aging peptide that’s actually the most trustworthy? Wrong question. NMN has the strongest human data and, notably, the most modest claims attached to it [1][2]. The boldest longevity stories rest on the thinnest evidence [3][6], and SS-31 actually failed its phase 3 trial outright [4][5]. Trust belongs to whoever is accountable for what’s in the vial, not to whichever molecule is trending.
Is any of this FDA-approved for aging? No. Epithalon, NMN, NAD+, SS-31, humanin, GHK-Cu, and thymosin alpha-1 are not FDA-approved anti-aging therapies. Thymosin alpha-1 has approval in some countries for specific unrelated conditions, not for aging, and compounded medications are never FDA-approved finished drug products regardless of what compound is involved.
Where should a cautious person actually start? With a licensed clinician between them and any of this. After the crackdown, that means a physician-supervised telehealth model where an intake actually captures history, a prescription only follows if warranted, and a licensed pharmacy compounds the result. On the factors above, that’s the FormBlends and HealthRX tier. Everything else sits below it, no matter how transparent any individual seller’s certificate looks.
Do peptides for anti-aging actually work, or is it mostly marketing?
Some show real, measurable effects, and the strength of that evidence varies enormously by peptide and by how it’s delivered. Topical peptides like matrikines have decent clinical backing for modest wrinkle reduction. Injectable peptides such as BPC-157 or epithalon are far less studied in people, and most of what backs them comes from animal work or small pilot studies. Promising in places. Proven across the board, no.
Are peptides for anti-aging safe to use?
Depends entirely on which peptide, what dose, where it came from, and whether a physician is anywhere in the loop. Topical peptides sold in cosmetics, well-characterized, carry a reasonable safety record. Injectable research-grade peptides bought from unregulated vendors are a different animal, since purity and dosing accuracy aren’t guaranteed at all. The honest answer is that long-term human safety data for most injectable anti-aging peptides doesn’t exist yet, full stop, and that absence should weigh on any decision.
Given the regulatory shift, what are actually the best anti-aging peptides right now?
There’s no single best answer, because the goals differ. For skin texture specifically, topical argireline and copper peptides have the most consistent cosmetic evidence behind them. For systemic goals like recovery or body composition, sermorelin and tesamorelin have the longest clinical track record among growth-hormone-releasing peptides. Post-crackdown, the more practical answer is that peptides with an established pharmaceutical history are simply easier to access legally, and come with more accountability around dosing than the newer, louder names.
Where can someone actually buy these legally after the crackdown?
The clearest legal path for anything injectable is a physician’s prescription filled by a licensed compounding pharmacy. FormBlends operates in that physician-supervised compounding space, meaning there’s real accountability attached to what’s in the vial. Buying from research-chemical websites is a legal gray area at best now, and the purity risk was always there regardless of the FDA’s attention. Cosmetic peptides sold in serums remain fine to buy over the counter, unaffected by any of this.
References
- Yi L, Maier AB, Tao R, et al. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/
- Wang X, Yang Q, Liao Q, et al. The therapeutic perspective of NAD+ precursors in age-related diseases. Biochemical and Biophysical Research Communications. 2024;702:149590. https://www.sciencedirect.com/science/article/pii/S0006291X24001256
- Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003;24(3-4):233-240.
- Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
- Reata Pharmaceuticals/Stealth BioTherapeutics. MMPOWER-3 phase 3 trial of elamipretide in primary mitochondrial myopathy (NCT03323749). ClinicalTrials.gov.
- Yen K, Mehta HH, Kim SJ, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(11):11185-11199.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987.
- Liu D, Wang X, Zhang H, et al. The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583.
- U.S. Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. March 3, 2026.
- U.S. Food and Drug Administration. Warning Letters: research-peptide sellers (e.g., Mile High Compounds LLC, MARCS-CMS 721600; Gram Peptides, 721806; Prime Sciences, 721805). March 31, 2026.
Written by Greta Zamora, science writer. Not a doctor, just a reader who chases the paper trail. Last reviewed March 2026.
For informational purposes. Any new treatment should be reviewed by a licensed professional first.
